A total of 157 patients were treated with tobramycin or amikacin in a controlled prospective randomized trial. Dosages were adjusted to renal function according to a nomogram. Trough and peak aminoglycoside levels were available at the end of the trial. Of the above total, 113 recipients of nine or more doses of tobramycin or six or more doses of amikacin, without other apparent cause of renal failure, were evaluated for nephrotoxicity. Thirty-six patients were evaluated for auditory toxicity. The patients in groups evaluated for either nephrotoxicity or auditory toxicity were similar with respect to intensity and etiology of bacterial disease, concurrent exposure to other antimicrobial drugs, a,ge and sex distribution, initial serum creatinine level, and total dose and duration of antimicrobial therapy. Nephrotoxicity of similar severity developed in 4 of 59 (6.8%) recipients of tobramycin and in 7 of 54 (13.1%o) recipients of amikacin (P > 0.05). Mild auditory toxicity developed in 3 of 19 (15.7%) recipients of tobramycin and in 2 of 17 (11.7%) recipients of amikacin (P > 0.05). When patients with abnormally high mean trough or peak aminoglycoside levels were excluded from comparison, nephrotoxicity was 6.12 and 5.12% (P > 0.05) and auditory toxicity was 17.6 and 7.69%6 (P > 0.05) in the groups given tobramycin and amikacin, respectively, We conclude that the nephrotoxicity and auditory toxicity of amniacin and tobramycin are not significantly different and that such toxicities are indeed infrequent events when the dosages of these drugs are adjusted to hold blood levels within the safe boundaries suggested by the studies of others.
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Despite the introduction of new cephalosporins and penicillins, aminoglycosides still have their place in the therapeutic armamentarium (W. L. Hewitt and S. C. Schimpf, Abstr. 12th Int. Congr. Chemother. 1981), nephrotoxicity and ototoxicity being the major factors limiting their clinical utility (19, 33) . Although gentamicin has been the first-choice aminoglycoside for years (2), tobramycin is at least as effective and seems to be significantly less toxic in laboratory animals (1, 3, 8, 16, 20, 37) and in clinical studies (14i 17, 26, 29, 30, 33, 35, 37) . Amikacin, effective in the treatment of infections with gentamicin-and tobramycin-resistant gram-negative ba. cimli (21-23, 31, 34) , has a-, proven role as a reserve drug (1, 21, 23) . It may become the aminoglycoside of first choice for nosocoial and life-threatening community-acquired diseases in those hospitals and geographical areas where there is a high incidence of infections with gentamicin-resistant gram-negative bacilli. However, to date there has been no prospective randomized study of the comparative toxicitie$ of tobramycin and amikacin in an unselected group of patients (5, 21) . The results of the first prospective randomized controlled trial comparing the nephrotoxicity and auditory toxicity of tobramycin and amikacin have been set forth in this report. of detection was 0.4 ag/ml for tobramycin and 1.5 pg/ml for amikacin. The within-and between-assay coefficients of variation were 3.5 and 7.2% for tobramycin at 6 pg/ml and 4.2 and 7.6% for amikacin at 15 pg/ml. Determinations were performed in stored frozen serum samples that had been kept at -20°C for not more than 3 months. Results were not available until the end of the trial. Trough and peak aminoglycoside levels above 2 and 10 pg/ml, respectively, for tobramycin and above 10 and 40 pg/ml, respectively, for amikacin are potentially toxic (21, 33) and, for the purpose of this study, were considered as abnormally high. To correct the differences in maintenance dosage and in patterms of administration, total dose and levels of amikacin, when compared with those of tobramycin were divided by factors of 3.5 and 5, respectively. Serum creatinine was measured before therapy and on every third day until 2 days after cessation of therapy or until patient death. Additional follow-ups were not performed regularly. Nephrotoxicity was defined as a rise in serum creatinine of 0.5 mg/dl or more if the initial level was less than 3 mg/dl or a rise of 1 mg/dl or more if the initial creatinine level was 3 mg/dl or above (15, 33) . The rise was estimated by subtracting the creatinine level before therapy from the highest creatinine level during therapy. Creatinine was measured by a modified Jaffe method in an automated multichannel analyzer (Prisma; Clinicon, Bromma, Sweden); the daily variation at our institution was less than 0.2 mg/dl.
MATERLS AND METHODS

Patnts
Audiograms were performed in a soundproof auditory test chamber with an audiometer (Amplaid 300; Amplaid SpA, Milan, Italy) at 250 to 8,000 Hz on day 1 or 2 and day 7 of therapy and every 7 days if therapy continued. Slight auditory toxicity was defined as a decrease in auditory threshold of 15 dB at any frequency in the range of 250 to 8,000 Hz either unilaterally or bilaterally. Auditory toxicity was considered mild if a decrease in auditory threshold was 20 dB or more at any frequency in the same range.
Previously reported criteria were followed for diagnosing the infections and for measuring the clinical response (32, 36) . Each treated patient was assigned to only one category or type of infection. Patients with positive blood cultures from an unknown origin or from an endovascular source were reported as having bacteremia.
Statistical methods. Chi-square tests, with the Yates correction when necessary, and Fisher's exact tests were used to compare proportions, and Student's t test was used to compare means. A two-tailed analysis was decided upon before the study began. We selected our sample size to detect differences of nephrotoxicity of about 12%o from an estimated control incidence of 15%, with a probability of an alpha error of less than 0.05 and a beta-type error of less than 0.25.
RESULTS
Of the 157 patients initially entered in the trial, 30 (12 given tobramycin and 18 given amikacin) were excluded because they received fewer than six doses of amikacin or nine doses of tobramycin, and 14 (7 given tobramycin and 7 given amikacin) were excluded because they had another potential cause of acute renal failure. The other causes of renal failure were hypotension or shock in eight patients, dehydration in three, and hepatorenal syndrome in three.
The nephrotoxicities of tobramycin and amikacin were then compared in the remaining 113 patients, 59 given tobramycin and 54 given amikacin. The two groups did not differ (Table 1) in mean age, sex ratio, initial creatinine levels, duration of therapy, total dose and mean trough and peak levels of aminoglycosides, presence of previous renal disease, concurrent drug administration, and causative agents. The mean increase in serum creatinine level was similar in both treatment groups, 0.042 ± 0.24 mg/dl in the group given tobramycin versus 0.23 ± 1.13 mg/dl in the group given amikacin (P > 0.05, not significant). Nephrotoxicity developed in 6.8% of the patients given tobramycin and 13% of the patients given amikacin, (Table 1, P > 0.05, not significant). The severity of nephrotoxicity was also similar in both treatment groups. Among the patients who developed nephrotoxicity, the mean increases in serum creatinine levels in the group given tobramycin (0.6 ± 0.2 mg/dl) were similar to the mean increases in the group given amikacin (0.8 ± 0.47 mg/dl) (P > 0.05). Among the patients with nephrotoxicity, two in the tobramycin group died and four in the amikacin group died. In no case did acute renal failure develop, and nephrotoxicity was not considered to be the cause of any of those deaths. When patients exhibiting nephrotoxicity were com- pared with those without nephrotoxicity, there were no differences with respect to age, sex ratio, duration of therapy, total dose, initial creatinine levels, peak and trough aminoglycoside levels, source of infection, and concurrent drug therapy. When patients with abnormally high levels of aminoglycoside were excluded from the comparison, nephrotoxicity appeared in 6.1% of the patients on tobramycin and in DISCUSSION Although toxicities of tobramycin and amikacin have been extensively studied previously (9, 10, 18, 21, 24) , they have never been compared in a prospective'randomized trial involving an unselected group of patients (21) . Similar rates of nephrotoxicity (ca. 20%'o) were found for tobramycin and amikacin in a prospective randomized trial designed primarily to compare clinical efficacy in patients with cancer (12) . In this trial, the criteria for nephrotoxicity were not strictly defined, and no attempt was made to evaluate auditory toxicity. In another prospective nonrandomized trial in an intensive care unit, the incidences of nephrotoxocity were 25 , 22.8, and 36.3% among recipients of amikacin, tobramycin, and gentamicin, respectively (26) . There were only 16 patients in the amikacin group; how they were selected to receive this antibiotic is unclear (21, 26) .
The dosage of the aminoglycoside was strictly defined in our trial, and adjusted dosages followed the guidelines of Sarubbi and Hull (28) . We believe that this is a realistic approach to VOL. 23, 1983 on October 18, 2017 by guest http://aac.asm.org/ Downloaded from 
